Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, multilayer - excipient ingredients: sodium hydroxide; mannitol; povidone; lactose monohydrate; meglumine; magnesium stearate; sodium stearylfumarate; purified water; iron oxide red - telmisartan hct appl is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: meglumine; sodium hydroxide; mannitol; povidone; magnesium stearate; lactose monohydrate; purified water; sodium stearylfumarate; colour - telmisartan hct apa is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, multilayer - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; sodium hydroxide; mannitol; meglumine; sodium stearylfumarate; purified water; iron oxide red - telmisartan hct apa is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, multilayer - excipient ingredients: sodium hydroxide; mannitol; povidone; lactose monohydrate; meglumine; magnesium stearate; sodium stearylfumarate; purified water; iron oxide red - telmisartan hct apa is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; povidone; sodium hydroxide; magnesium stearate; mannitol - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; magnesium stearate; mannitol; povidone; meglumine - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, film coated - excipient ingredients: iron oxide red; povidone; meglumine; magnesium stearate; sodium hydroxide; lactose; iron oxide yellow; macrogol poly(vinyl alcohol) grafted polymer; citric acid monohydrate; colloidal anhydrous silica; lactose monohydrate; crospovidone - telmisartan/hct sandoz? is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - telmisartan 40 mg - telmisartan and hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention,

USA - engelsk - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - telmisartan 40 mg - telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committ

USA - engelsk - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - telmisartan 40 mg - telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committ